Χώρα: Ιρλανδία
Γλώσσα: Αγγλικά
Πηγή: HPRA (Health Products Regulatory Authority)
PYRIDOSTIGMINE BROMIDE
Meda Health Sales Ireland Limited
N07AA02
PYRIDOSTIGMINE BROMIDE
60 Milligram
Tablets
Product subject to prescription which may be renewed (B)
Anticholinesterases
Authorised
2011-06-10
PACKAGE LEAFLET: INFORMATION FOR THE USER MESTINON 60 MG TABLETS Pyridostigmine bromide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1. What Mestinon tablets are and what they are used for 2. What you need to know before you take Mestinon tablets 3. How to take Mestinon tablets 4. Possible side effects 5. How to store Mestinon tablets 6. Contents of the pack and other information 1. WHAT MESTINON TABLETS ARE AND WHAT THEY ARE USED FOR Mestinon tablets contain the active ingredient pyridostigmine, which belongs to a group of medicines called anticholinesterases, which improve the communication between the nerves and the muscles. Mestinon tablets are used for: Treatment of myasthenia gravis – a disease of the immune system causing muscle weakness Paralytic ileus – a condition where the digestive tract does not work because its muscles are paralysed Urinary retention after surgery – failure to urinate cause by an anaesthetic or certain types or surgery. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MESTINON TABLETS DO NOT TAKE MESTINON TABLETS: - If your digestive tract is twisted or blocked by an obstruction. - If you cannot pass urine because of an obstruction. - If you are allergic to pyrido Διαβάστε το πλήρες έγγραφο
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mestinon 60mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Tablet contains 60.0mg pyridostigmine bromide. Each Tablet contains 60.75mg lactose monohydrate. _For excipients, see section 6.1._ 3 PHARMACEUTICAL FORM Tablet White to off-white, round, biplanar, bevel-edged tablets imprinted with “V” M60 across one face and with two break marks forming a cross on the other. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Myasthenia gravis, paralytic ileus and post-operative urinary retention. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Myasthenia gravis_ _Adults_ Doses of 30 to 120mg are given at intervals throughout the day when maximum strength is needed (for example, on rising and before mealtimes). The usual duration of action of a dose is 3 to 4 hours in the daytime but a longer effect (6 hours) is often obtained with a dose taken on retiring for bed. The total daily dose is usually in the range of 5 - 20 tablets but doses higher than these may be needed by some patients. _Children_ Children under 6 years old should receive an initial dose of half a tablet (30mg) of Mestinon; children 6-12 years old should receive one tablet (60mg). Dosage should be increased gradually, in increments of 15-30mg daily, until maximum improvement is obtained. Total daily requirements are usually in the range of 30 - 360mg _Other Indications (paralytic ileus)_ _Adults_ The usual dose is 1 to 4 tablets (60 to 240mg) per day. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Διαβάστε το πλήρες έγγραφο